Open Access

Chemotherapy of metastatic hepatoid adenocarcinoma: Literature review and two case reports with cisplatin etoposide

  • Authors:
    • Victor Simmet
    • Margot Noblecourt
    • Thibaut Lizée
    • Benjamin Morvant
    • Sylvie Girault
    • Patrick Soulié
    • Olivier Capitain
  • View Affiliations

  • Published online on: October 25, 2017     https://doi.org/10.3892/ol.2017.7263
  • Pages:48-54
  • Copyright: © Simmet et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: HTML 0 views | PDF 0 views
0

Abstract

Hepatoid adenocarcinoma (HAC) is a rare and aggressive cancer subtype with a poor prognosis under metastatic conditions. Currently, there is no specific chemotherapy treatment protocol for advanced stages of the disease. This review evaluates two cases of HAC of gastric cardia with synchronous liver metastasis, which were successfully treated by chemotherapy with cisplatin (25 mg/m2 each day) (day 1 to day 3) and etoposide (100 mg/m2) (day 1 to day 3), every three weeks. A structured literary evaluation and reviewed pertinent articles are additionally presented to analyse the different approaches for the treatment of metastatic HAC (mHAC). The two described case reports demonstrated good partial responses to treatment and one of the two patients exhibited a good prognosis after a 9‑year follow‑up. A total of 20 case reports concerning the use of chemotherapy in mHAC were presented in the literature, 11 of which were regarding gastric HACs. The two aforementioned cases result in a total of 22 reports, 11 of which exhibited objective responses to chemotherapy, 8 patients demonstrated a partial response and 3 a complete response. The cisplatin‑based regimen concerned 55% (12/22) patients and enabled 9 (75%) to exhibit a partial or complete response. A total of three patients exhibited a good prognosis in the long‑term follow‑up, all of them treated with a cisplatin‑based regimen. It was demonstrated that the usual digestive regimens were not efficient in the treatment of HAC. In the absence of prospective trials, it may be hypothesized that cisplatin‑based chemotherapy may be the most efficient first‑line treatment in mHAC, with a 75% patient response, in accordance with the literature and follow‑up cases.

Related Articles

Journal Cover

January 2018
Volume 15 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

2016 Impact Factor: 1.39
Ranked #68/217 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Simmet, V., Noblecourt, M., Lizée, T., Morvant, B., Girault, S., Soulié, P., & Capitain, O. (2018). Chemotherapy of metastatic hepatoid adenocarcinoma: Literature review and two case reports with cisplatin etoposide. Oncology Letters, 15, 48-54. https://doi.org/10.3892/ol.2017.7263
MLA
Simmet, V., Noblecourt, M., Lizée, T., Morvant, B., Girault, S., Soulié, P., Capitain, O."Chemotherapy of metastatic hepatoid adenocarcinoma: Literature review and two case reports with cisplatin etoposide". Oncology Letters 15.1 (2018): 48-54.
Chicago
Simmet, V., Noblecourt, M., Lizée, T., Morvant, B., Girault, S., Soulié, P., Capitain, O."Chemotherapy of metastatic hepatoid adenocarcinoma: Literature review and two case reports with cisplatin etoposide". Oncology Letters 15, no. 1 (2018): 48-54. https://doi.org/10.3892/ol.2017.7263